SCHEMBL17079261

SCHEMBL17079261

C[C@@H](O)c1nnc(CCNC(=O)c2cc(-c3ccccc3)on2)s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.59
HIF1A Q16665 3/20 0.56
POLB P06746 1/20 0.54
MAPT P10636 2/20 0.52
RAB9A P51151 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MAPK1 P28482 2/20 0.51
KMT2A Q03164 2/20 0.51
HDAC3 O15379 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
NPC1 O15118 3/20 0.49
LMNA P02545 2/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17079262 1.00 FAAH (0.59) FAAHHIF1APOLBMAPTRAB9A
SCHEMBL17079465 1.00 FAAH (0.59) FAAHHIF1APOLBMAPTRAB9A
SCHEMBL18356126 0.93 FAAH (0.60) FAAHHIF1APOLBMAPTRAB9A
SCHEMBL19457871 0.91 FAAH (0.58) FAAHHIF1APOLBMAPTRAB9A
SCHEMBL19457866 0.91 FAAH (0.58) FAAHHIF1APOLBMAPTRAB9A
SCHEMBL17087746 0.90 FAAH (0.59) FAAHHIF1APOLBMAPTRAB9A
SCHEMBL17087745 0.90 FAAH (0.59) FAAHHIF1APOLBMAPTRAB9A
SCHEMBL17079321 0.89 POLB (0.56) FAAHHIF1APOLBMAPTRAB9A
SCHEMBL17087761 0.89 POLB (0.56) FAAHHIF1APOLBMAPTRAB9A
SCHEMBL19457906 0.87 FAAH (0.54) FAAHHIF1APOLBMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9790219-B2 Compounds, compositions, and methods for increasing CFTR activity PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
EP-3116501-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY Proteostasis Therapeutics, Inc. (US) 2017-01-18 EP disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. 2017-01-05 US disclosed
WO-2015138909-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-09-17 WO disclosed
WO-2015138909-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY PROTEOSTASIS THERAPEUTICS, INC. (US) 2015-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001993-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY CFTR, ABCB4, KEAP1 FAAH 1749/4885HIF1A 2336/4885POLB 1649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.